Sandbox:Hannan: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 19: Line 19:
|Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of
|Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of
PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2
PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2
* Myeloid/lymphoid neoplasms with PDGFRA rearrangement
* <small>Myeloid/lymphoid neoplasms with PDGFRA rearrangement</small>
* Myeloid/lymphoid neoplasms with PDGFRB rearrangement
* <small>Myeloid/lymphoid neoplasms with PDGFRB rearrangement</small>
* Myeloid/lymphoid neoplasms with FGFR1 rearrangement
* <small>Myeloid/lymphoid neoplasms with FGFR1 rearrangement</small>
* Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK
* <small>Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK</small>
|
|
|
|
Line 32: Line 32:
|-
|-
|Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
|Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
* Chronic myelomonocytic leukemia (CMML)
* <small>Chronic myelomonocytic leukemia (CMML)</small>
* Atypical chronic myeloid leukemia (aCML), BCR-ABL1-
* <small>Atypical chronic myeloid leukemia (aCML), BCR-ABL1-</small>
* Juvenile myelomonocytic leukemia (JMML)
* <small>Juvenile myelomonocytic leukemia (JMML)</small>
* MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
* <small>MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)</small>
* MDS/MPN, unclassifiable
* <small>MDS/MPN, unclassifiable</small>
|
|
|
|
Line 46: Line 46:
|-
|-
|Myelodysplastic syndromes (MDS)
|Myelodysplastic syndromes (MDS)
* MDS with single lineage dysplasia
* <small>MDS with single lineage dysplasia</small>
* MDS with ring sideroblasts (MDS-RS)
* <small>MDS with ring sideroblasts (MDS-RS)</small>
* MDS-RS and single lineage dysplasia
* <small>MDS-RS and single lineage dysplasia</small>
* MDS-RS and multilineage dysplasia
* <small>MDS-RS and multilineage dysplasia</small>
* MDS with multilineage dysplasia
* <small>MDS with multilineage dysplasia</small>
* MDS with excess blasts
* <small>MDS with excess blasts</small>
* MDS with isolated del(5q)
* <small>MDS with isolated del(5q)</small>
* MDS, unclassifiable
* <small>MDS, unclassifiable</small>
* Provisional entity: Refractory cytopenia of childhood
* <small>Provisional entity: Refractory cytopenia of childhood</small>
* Myeloid neoplasms with germ line predisposition
* <small>Myeloid neoplasms with germ line predisposition</small>
|
|
|
|
Line 66: Line 66:
|Acute myeloid leukemia (AML) and related neoplasms
|Acute myeloid leukemia (AML) and related neoplasms
* AML with recurrent genetic abnormalities
* AML with recurrent genetic abnormalities
# AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
# <small>AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1</small>
# AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11
# <small>AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11</small>
# APL with PML-RARA
# <small>APL with PML-RARA</small>
# AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A
# <small>AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A</small>
# AML with t(6;9)(p23;q34.1);DEK-NUP214
# <small>AML with t(6;9)(p23;q34.1);DEK-NUP214</small>
# AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM
# <small>AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM</small>
# AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1
# <small>AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1</small>
# Provisional entity: AML with BCR-ABL1
# <small>Provisional entity: AML with BCR-ABL1</small>
# AML with mutated NPM1
# <small>AML with mutated NPM1</small>
# AML with biallelic mutations of CEBPA
# <small>AML with biallelic mutations of CEBPA</small>
# Provisional entity: AML with mutated RUNX1
# <small>Provisional entity: AML</small> <small>with mutated RUNX1</small>
* AML with myelodysplasia-related changes
* AML with myelodysplasia-related changes
* Therapy-related myeloid neoplasms
* Therapy-related myeloid neoplasms
* AML, NOS
* AML, NOS
# AML with minimal differentiation
# <small>AML with minimal differentiation</small>
# AML without maturation
# <small>AML without maturation</small>
# AML with maturation
# <small>AML with maturation</small>
# Acute myelomonocytic leukemia
# <small>Acute myelomonocytic leukemia</small>
# Acute monoblastic/monocytic leukemia
# <small>Acute monoblastic/monocytic leukemia</small>
# Pure erythroid leukemia
# <small>Pure erythroid leukemia</small>
# Acute megakaryoblastic leukemia
# <small>Acute megakaryoblastic leukemia</small>
# Acute basophilic leukemia
# <small>Acute basophilic leukemia</small>
# Acute panmyelosis with myelofibrosis
# <small>Acute panmyelosis with myelofibrosis</small>
* Myeloid sarcoma
* Myeloid sarcoma
* Myeloid proliferations related to Down syndrome
* Myeloid proliferations related to Down syndrome
# Transient abnormal myelopoiesis (TAM)
# <small>Transient abnormal myelopoiesis (TAM)</small>
# Myeloid leukemia associated with Down syndrome
# <small>Myeloid leukemia associated with Down syndrome</small>
|
|
|
|
Line 125: Line 125:
|-
|-
|B-lymphoblastic leukemia/lymphoma
|B-lymphoblastic leukemia/lymphoma
* B-lymphoblastic leukemia/lymphoma, NOS
* <small>B-lymphoblastic leukemia/lymphoma, NOS</small>
* B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities
* <small>B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities</small>
* B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1
* <small>B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1</small>
* B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged
* <small>B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged</small>
* B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1);ETV6-RUNX1
* <small>B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1);ETV6-RUNX1</small>
* B-lymphoblastic leukemia/lymphoma with hyperdiploidy
* <small>B-lymphoblastic leukemia/lymphoma with hyperdiploidy</small>
* B-lymphoblastic leukemia/lymphoma with hypodiploidy
* <small>B-lymphoblastic leukemia/lymphoma with hypodiploidy</small>
* B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH
* <small>B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH</small>
* B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1
* <small>B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1</small>
* Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like
* <small>Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like</small>
* Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP
* <small>Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP</small>
|
|
|
|
Line 145: Line 145:
|-
|-
|T-lymphoblastic leukemia/lymphoma
|T-lymphoblastic leukemia/lymphoma
* Provisional entity: Early T-cell precursor lymphoblastic leukemia
* <small>Provisional entity: Early T-cell precursor lymphoblastic leukemia</small>
* Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymph
* <small>Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymph</small>
|
|
|
|

Revision as of 12:44, 15 January 2019

Other myeloid neoplasm and acute leukemia Clinical manifestations Diagnosis Other features
Symptoms Physical examination Lab findings Bone marrow biopsy Gold standard Other investigations
Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of

PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2

  • Myeloid/lymphoid neoplasms with PDGFRA rearrangement
  • Myeloid/lymphoid neoplasms with PDGFRB rearrangement
  • Myeloid/lymphoid neoplasms with FGFR1 rearrangement
  • Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
  • Chronic myelomonocytic leukemia (CMML)
  • Atypical chronic myeloid leukemia (aCML), BCR-ABL1-
  • Juvenile myelomonocytic leukemia (JMML)
  • MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
  • MDS/MPN, unclassifiable
Myelodysplastic syndromes (MDS)
  • MDS with single lineage dysplasia
  • MDS with ring sideroblasts (MDS-RS)
  • MDS-RS and single lineage dysplasia
  • MDS-RS and multilineage dysplasia
  • MDS with multilineage dysplasia
  • MDS with excess blasts
  • MDS with isolated del(5q)
  • MDS, unclassifiable
  • Provisional entity: Refractory cytopenia of childhood
  • Myeloid neoplasms with germ line predisposition
Acute myeloid leukemia (AML) and related neoplasms
  • AML with recurrent genetic abnormalities
  1. AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
  2. AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11
  3. APL with PML-RARA
  4. AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A
  5. AML with t(6;9)(p23;q34.1);DEK-NUP214
  6. AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM
  7. AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1
  8. Provisional entity: AML with BCR-ABL1
  9. AML with mutated NPM1
  10. AML with biallelic mutations of CEBPA
  11. Provisional entity: AML with mutated RUNX1
  • AML with myelodysplasia-related changes
  • Therapy-related myeloid neoplasms
  • AML, NOS
  1. AML with minimal differentiation
  2. AML without maturation
  3. AML with maturation
  4. Acute myelomonocytic leukemia
  5. Acute monoblastic/monocytic leukemia
  6. Pure erythroid leukemia
  7. Acute megakaryoblastic leukemia
  8. Acute basophilic leukemia
  9. Acute panmyelosis with myelofibrosis
  • Myeloid sarcoma
  • Myeloid proliferations related to Down syndrome
  1. Transient abnormal myelopoiesis (TAM)
  2. Myeloid leukemia associated with Down syndrome
Blastic plasmacytoid dendritic cell neoplasm
Acute leukemias of ambiguous lineage
  • Acute undifferentiated leukemia
  • Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2);BCR-ABL1
  • MPAL with t(v;11q23.3);KMT2A rearranged
  • MPAL, B/myeloid, NOS
  • MPAL, T/myeloid, NO
B-lymphoblastic leukemia/lymphoma
  • B-lymphoblastic leukemia/lymphoma, NOS
  • B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities
  • B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1
  • B-lymphoblastic leukemia/lymphoma with t(v;11q23.3);KMT2A rearranged
  • B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1);ETV6-RUNX1
  • B-lymphoblastic leukemia/lymphoma with hyperdiploidy
  • B-lymphoblastic leukemia/lymphoma with hypodiploidy
  • B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3) IL3-IGH
  • B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1
  • Provisional entity: B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like
  • Provisional entity: B-lymphoblastic leukemia/lymphoma with iAMP
T-lymphoblastic leukemia/lymphoma
  • Provisional entity: Early T-cell precursor lymphoblastic leukemia
  • Provisional entity: Natural killer (NK) cell lymphoblastic leukemia/lymph
Myeloproliferative neoplasms (MPN) Clinical manifestations Diagnosis Other Features
Symptoms Physical examination Laboratory Findings Bone Marrow Biopsy Gold Standard Other investigations
Chronic myeloid leukemia

(CML), BCR-ABL1+

Chronic neutrophilic leukemia (CNL)
Polycythemia vera (PV)
Primary myelofibrosis (PMF)
  • prefibrotic/early stage
  • overt fibrotic stage
Essential thrombocythemia (ET)
Chronic eosinophilic leukemia, not otherwise specified (NOS)
MPN, unclassifiable
Mastocytosis